银杏叶注射液治疗晚期肺癌患者血液高凝状态的疗效观察

医学研究与教育 ›› 2014, Vol. 31 ›› Issue (6): 53-56.

银杏叶注射液治疗晚期肺癌患者血液高凝状态的疗效观察

罗纯¹，张建军²，胡玲²，王坤杰²，刘涛³，韩月娟³

1. 涞水县妇幼保健院，河北涞水 074100；2. 河北大学附属医院，河北保定 071000；3. 高阳县医院，河北高阳 075000

出版日期:2014-12-25 发布日期:2014-12-25
通讯作者: 张建军（1976—），男，河北保定人，主治医师，硕士，主要从事外科学、急诊医学研究。E-mail: 57461548@qq.com
作者简介:罗纯（1976—），女，河北涞水人，主管护师，主要从事临床护理研究。E-mail: 27188034@qq.com

Clinical observation of Ginkgo biloba injection in treating hypercoagulable states of patients with advanced lung cancer

LUO Chun¹, ZHANG Jianjun², HU Ling², WANG Kunjie², LIU Tao³, HAN Yuejuan³

1. Maternal and Child Health Care Center of LaiShui, Laishui 074100, China; 2. Affiliated Hospital of Hebei University, Baoding 071000, China; 3. Hospital of Gaoyang County, Gaoyang 075000, China

Online:2014-12-25 Published:2014-12-25

摘要/Abstract

摘要： 目的观察银杏叶注射液对于肺癌患者血液高凝状态的疗效及其安全性。方法选取2010 年10 月至2014 年10月河北大学附属医院收治 109 例晚期肺癌患者作为研究对象，随机分成治疗组（50 例）和对照组（59 例）。对照组仅行全身化疗，治疗组予以全身化疗联合应用银杏叶注射液，7 d 为 1 个疗程，治疗 2 个疗程后对比 2 组疗效及 Fib（血浆纤维蛋白原）、D-D（D- 二聚体）水平。结果治疗组的改善率为 81.36%（48/59），对照组的为 26%（13/50）；治疗组无效率为8.47%（5/59），对照组的为32%（16/50）；治疗组稳定率为10.17%（6/59），对照组的为42%（21/50）（均P<0.05）。治疗组治疗前和对照组治疗前Fib、D-D 水平差异无统计学意义（P>0.05），而治疗后的 Fib、D-D 均显著低于对照组治疗后的 Fib 、D-D，差异有统计学意义（P<0.05）。治疗组与对照组 Fib 和 D-D 水平治疗前后差值比较（P<0.05），治疗组疗效优于对照组。治疗组未出现明显不良反应。结论银杏叶注射液能改善肺癌患者血液高凝状态，疗效及安全性均较好。

关键词: 银杏叶注射液, 肺癌, 血液高凝状态

Abstract: Objective To observe the efficacy and safety of Ginkgo biloba injection in treating blood hypercoagulable state of patients with advanced lung cancer. Methods 109 cases with advanced lung cancer in the Affiliated Hospital of Hebei University were divided into experimental group (50 cases) and control group (59 cases) between 2010.10 to 2014.10. The patients of the control group were treated only with systemic chemotherapy, those of the experimental group were also treated with chemotherapy combined with Ginkgo biloba injection. Fib, D-D levels and curative effects were compared after 2 courses of treatment, which one period of treatment was 7 days. Results The improvement rate of experimental group was 81.36% (48/59), and 26% (13/50) in the control group. Inefficiency in the experimental group and control group was 8.47% (5/59) and 32% (16/50), and the stability factor was 10.17% (6/59) and 42% (21/50) ( both P<0.05). Comparing two groups, the Fib and D-D levels did not have any significant difference before treatment (P>0.05). However, the two levels of the experimental group were lower than those of the control group after treatment, and the difference was significant (P<0.05). The difference about the Fib and D-D levels before and after treatment between the experimental group and the control group was significant (P<0.05), showing that the curative effect of the experimental group was better than that of the control group.Experimental group did not appear obvious adverse reactions. Conclusion Ginkgo biloba injection can improve blood hypercoagulable state of patients with lung cancer, which is effective and safety.

Key words: ginkgo biloba injection, lung cancer, blood hypercoagulable state

中图分类号:

罗纯，张建军，胡玲，王坤杰，刘涛，韩月娟. 银杏叶注射液治疗晚期肺癌患者血液高凝状态的疗效观察[J]. 医学研究与教育, 2014, 31(6): 53-56.

LUO Chun, ZHANG Jianjun, HU Ling, WANG Kunjie, LIU Tao, HAN Yuejuan. Clinical observation of Ginkgo biloba injection in treating hypercoagulable states of patients with advanced lung cancer[J]. Medical Reserch and Education, 2014, 31(6): 53-56.

[1]	隋莲玉,殷小平,王佳宁. 肺癌脑转移MRI影像基因组学研究进展[J]. 医学研究与教育, 2022, 39(1): 25-34.
[2]	蔡静薇,张宇,殷小平. 影像组学在肺癌诊断方面的研究进展[J]. 医学研究与教育, 2021, 38(6): 27-35.
[3]	李鹤飞, 王海波, 李伟, 史鸿云, 贾友超. 外周血ctDNA基因突变对早中期非小细胞肺癌患者的诊断效能分析[J]. 医学研究与教育, 2020, 37(6): 23-28.
[4]	张金娥,池立伟,臧瑜. 晚期肺癌患者的症状群研究进展[J]. 医学研究与教育, 2016, 33(5): 49-52.
[5]	王颖,张晓鹏. PTEN表达与NSCLC生存预后的关系[J]. 医学研究与教育, 2014, 31(1): 21-23.
[6]	闫丹,李清娟,边建良. 肿瘤标志物联合CT在肺癌纵隔淋巴结转移诊断中的应用[J]. 医学研究与教育, 2013, 30(1): 43-47.
[7]	李远,张国伟,李海滨. 康莱特治疗非小细胞肺癌临床研究进展[J]. 医学研究与教育, 2011, 28(2): 77-80.
[8]	李文艳,杨宏莉,杨静,耿坤静. her2基因在肺癌中的研究进展[J]. 医学研究与教育, 2010, 27(4): 83-86.
[9]	宋子正,刘新良,张红岩,商琰红,徐妍. 艾迪注射液联合GP方案治疗中晚期非小细胞肺癌疗效观察[J]. 医学研究与教育, 2009, 26(5): 36-37.
[10]	周斌,王晔兴,郭志敏,宫强,王云,李贲. 西黄消癥胶囊联合化疗在Ⅲ期非小细胞肺癌治疗中的应用[J]. 医学研究与教育, 2009, 26(3): 26-28.